Glasgow prognostic score predicts therapeutic outcome after hepatic resection for hepatocellular carcinoma

  • Authors:
    • Hiroaki Shiba
    • Takashi Horiuchi
    • Taro Sakamoto
    • Kenei Furukawa
    • Yoshihiro Shirai
    • Tomonori Iida
    • Yuki Fujiwara
    • Koichiro Haruki
    • Katsuhiko Yanaga
  • View Affiliations

  • Published online on: April 28, 2017     https://doi.org/10.3892/ol.2017.6104
  • Pages: 293-298
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Systemic inflammation, as evidenced by the Glasgow prognostic score (GPS), predicts cancer‑specific survival in various cancer types. The aim of this study was to evaluate the significance of the GPS in the therapeutic outcome of the patient following surgical resection for hepatocellular carcinoma. In total, 144 patients underwent surgical resection for hepatocellular carcinoma. For the assessment of systemic inflammatory response using the GPS, patients were classified into three groups: Patients with normal serum albumin (<3.5 g/dl) and normal serum C‑reactive protein (CRP) (≤1.0 mg/dl) were classified as GPS 0 (n=76), those with low serum albumin (<3.5 g/dl) or elevated serum CRP (>1.0 mg/dl) were classified as GPS 1 (n=58), and those with low serum albumin (<3.5 g/dl) and elevated serum CRP (>1.0 mg/dl) were classified as GPS 2 (n=10). Retrospectively, the relationship between patient characteristics including GPS, disease‑free as well as overall survival were investigated. In disease‑free survival, GPS 2 (P=0.019), with a tumor number ≥3 (P=0.004), and positive portal or venous invasion (P=0.034) were independent predictors of cancer recurrence in multivariate analysis. In overall survival, GPS 1 (P=0.042), GPS 2 (P<0.001) and positive portal or venous invasion (P<0.001) were independent predictors of poor patient outcome according to multivariate analysis. To conclude, the GPS in patients with hepatocellular carcinoma is an independent prognostic predictor after hepatic resection.

Introduction

Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide, the seventh most common cancer, and the third leading cause of cancer-related deaths (1). Although operative mortality and morbidity of hepatic resection in patients with HCC have been minimized by advances in surgical techniques, instruments, and perioperative management, therapeutic outcomes remain unsatisfactory due to the high incidence of recurrence (2,3). Therefore, it is important to clarify the predictor of HCC recurrence and prognosis for decision making in additional adjuvant treatment after hepatic resection, preoperatively. Several investigators have reported tumor size, vascular invasion, intrahepatic metastasis, tumor markers, excessive blood loss, and allogenic blood transfusion as factors associated with recurrence of HCC (47). Unlike other solid malignancies, the prognosis of HCC is not solely dependent on tumor burden but also adversely influenced by impaired liver function secondary due to the underlying pathogenic condition (8).

The presence of the systemic inflammatory response is associated with poor therapeutic outcome in patients with malignant tumors. Several recent investigators reported that the systemic inflammatory response by the combination of serum C-reactive protein (CRP) and albumin concentrations, i.e., Glasgow prognostic score (GPS), predicts cancer-specific survival (914). We previously reported the GPS as a predictor of long-term therapeutic outcome for hepatobiliary malignancies, including carcinoma of the ampulla of Vater (15), gallbladder cancer (16), and unresectable colorectal cancer liver metastasis (17). However, there have been only few reports on the relationship between the GPS and long-term outcome after hepatic resection for HCC (18,19). In this study, we retrospectively evaluated whether the GPS predicts disease-free or overall survival after hepatic resection for HCC.

Patients and methods

Between January 2002 and December 2011, 159 patients underwent primary hepatic resection for HCC at the Department of Surgery, The Jikei University Hospital (Tokyo, Japan). Of these, 15 patients were excluded, nine due to additional procedures for other malignancies, six due to lack of data, leaving the remaining 144 patients for the study. Generally, the extent of hepatic resection was determined based on retention rate of indocyanine green at 15 min (ICGR15) before surgery and in reference to the hepatic reserve as described by Miyagawa et al (20).

Hemogram and chemistry profile were routinely measured for each patient preoperatively. For the assessment of systemic inflammatory response using the GPS, the patients were classified into three groups: Patients with normal albumin (≥3.5 g/dl) and normal CRP (≤1.0 mg/dl) as GPS 0, those with low albumin (<3.5 g/dl) or elevated CRP (>1.0 mg/dl) as GPS 1, and both low albumin (<3.5 g/dl) and elevated CRP (>1.0 mg/dl) as GPS 2. Patient characteristics were classified into two groups for log-rank test and the Cox proportional hazard regression model. Patient age was classified as <65 or ≥65 years. Body mass index (BMI) was classified as <25 or ≥25. Preoperative ICGR15 was classified as ≤10% or >10%. Preoperative serum α-fetoprotein (AFP) was classified as ≤20 or >20 ng/ml. The type of resection was classified as anatomical resection (extended lobectomy, lobectomy, segmentectomy or subsegmentectomy) or non-anatomical limited partial resection. Duration of operation was classified as <360 or ≥360 min. Blood loss was classified as <1,000 or ≥1,000 g. Maximal tumor diameter was classified as ≤2, >2 ≤5, or >5 cm.

We investigated the relation between clinicopathologic variables and GPS by univariate analysis. The factors consisted of the following 17 factors: Age, sex, BMI, hepatitis virus status, Child classification, preoperative ICGR15, preoperative serum AFP, type of resection, duration of operation, blood loss, red cell concentrate (RC) transfusion, fresh frozen plasma (FFP) transfusion, maximal tumor diameter, tumor number, portal or venous invasion, coexistent disease, and incidence of postoperative complications.

Next, we investigated the relation between clinicopathologic variables and disease-free as well as overall survival after hepatic resection for HCC by univariate and multivariate analyses. The factors consisted of the following 16 factors: Age, sex, BMI, hepatitis virus status, Child classification, preoperative ICGR15, preoperative serum AFP, type of resection, duration of operation, blood loss, RC transfusion, FFP transfusion, maximal tumor diameter, tumor number, portal or venous invasion, and the GPS grade.

Recurrence of HCC was defined as newly detected hypervascular hepatic or extrahepatic tumors by ultrasonography, computed tomography, magnetic resonance image or angiography, with or without increase in serum a-fetoprotein, or protein induced by vitamin K absence or antagonist-II. For recurrent HCC in the liver, repeated hepatic resection, local ablation therapy or transarterial chemoembolization was given based on hepatic functional reserve judged mainly by ICGR15 and the size, number as well as location of the recurrent tumors. Extrahepatic recurrence was mainly treated conservatively.

Pulmonary complications were defined as postoperative pneumonia; postoperative respiratory failure with pyrexia, dyspenia, and a pulmonary infiltrate on chest X-ray; or pleural effusion that required thoracentesis. Bile leakage was defined as a discharge of fluid with an increased bilirubin concentration (at least 3 times the serum bilirubin concentration measured at the same time) via the intra-abdominal drains on or after postoperative day 3 or as the need for radiologic intervention (i.e., interventional drainage) and relaparotomy for biliary collections and bile peritonitis, respectively (21). Surgical site infection was defined as surgical wound infection that affect superficial tissues (skin and subcutaneous layer) and the deeper tissues (deep incisional or organ-space) of the incision according to the Centers for Disease Control and Prevention definitions (22).

This retrospective study was approved by the Ethics Committee of Jikei University School of Medicine (no. 21–121).

Statistical analysis

Patients' characteristics were analyzed using the non-paired Student's t-test and Chi-square test. Survival analyses were performed using Kaplan-Meier method, the Log-rank test, and the Cox proportional regression model with backward elimination stepwise approach. All P-values were considered statistically significant when the associated probability was less than 0.05. These analyses were conducted using IBM® SPSS statistics version 20.0 (IBM Japan, Tokyo, Japan).

Results

Patient characteristics, and univariate analysis of the association between clinicopathologic variables and Glasgow prognostic score

Patient characteristics, univariate analysis of the relationship between clinicopathologic variables and the GPS grade are outlined in Table I. Among the study population, GPS consisted of GPS 0 in 76, GPS 1 in 58 (low albumin; n=8, elevated CRP; n=50), and GPS 2 in 10 patients, respectively. In this study, the five-year disease-free and overall survival rates after hepatic resection for HCC were 32.9 and 74.5%, respectively. In univariate analysis of the relationship between clinicopathologic variables and the GPS grade, maximal tumor diameter was positively associated with the GPS grade (P=0.002). Ratio of patients with Child classification B tended to be positively associated with the GPS grade, which however did not achieved significance (P=0.053). Coexistent diabetes mellitus was positively associated with the GPS grade (P=0.008). Post-operative complications developed in 43 of 144 patients (29.9%), consisting of pulmonary complications in 11 (7.6%), bile leakage in 12, (8.3%), massive ascites in 7 (4.9%), and surgical site infection (SSI) in 11 patients (7.6%), respectively. The GPS grade was negatively associated with the incidence of SSI (P=0.021). Other complications were comparable among the three GPS grades. In-hospital mortality was 3 of 144 patients (2.1%), consisting of postoperative liver failure in two (1.4%) and sepsis in one patient (0.7%), respectively.

Table I.

Patients' characteristics, and univariate analysis of clinicopathologic variables in relation to Glasgow prognostic score after elective hepatic resection for hepatocellular carcinoma.

Table I.

Patients' characteristics, and univariate analysis of clinicopathologic variables in relation to Glasgow prognostic score after elective hepatic resection for hepatocellular carcinoma.

Glasgow prognostic score

P-value (univariate)
FactorAll patients0 (n=76)1 (n=58)2 (n=10)
Age (years)63 (57–71)a63 (56–68)66 (58–72)66 (62–71)0.246
Sex (male:female)125:1966:1049:910:00.408
Body mass index23.3 (21.3–25.4)22.9 (21.2–25.4)23.3 (21.5–25.0)25.3 (23.8–26.9)0.159
Hepatitis virus (HBV:HCV:none)38:55:5123:32:2113:21:242:2:60.218
Child classification (A:B)134:1074:252:68:20.053
ICGR15 (%)12 (8–19)12 (8–16)13 (9–23)13 (8–21)0.149
Serum α-fetoprotein (ng/ml)13.7 (5–119.5)11 (4.8–26.2)38 (6.7–330.0)21.5 (10.9–36.7)0.183
Type of resection (anatomical:partial)78:6643:3330:285:50.824
Duration of operation (min)371 (262–480)377 (239–480)368 (285–473)315 (263–452)0.692
Intraoperative blood loss (g)682 (308–1403)622 (325–1136)1,018 (352–1,845)360 (183–760)0.125
RC transfusion (present:absent)33:11113:6318:402:80.160
FFP transfusion (present:absent)26:11812:6412:462:80.755
Tumor diameter (cm)3.2 (2.2–5.5)3.0 (2.2–4.2)4.0 (2.4–7.4)4.0 (2.6–8.2)0.002
Tumor number (single:double:triple or more)114:13:1762:9:543:4:119:0:10.161
Portal or venous invasion (positive:negative)33:11115:6116:422:80.549
Coexistent disease
  Hypertension (present:absent)64:8034:4227:313:70.621
  Diabetes mellitus (present:absent)40:10419:5714:447:30.008
  Hyperlipidemia (present:absent)18:12610:666:522:80.673
Postoperative complications
  Pulmonary complications (present:absent)11:1335:714:542:80.312
  Massive ascites (present:absent)   7:1373:734:54   0:100.558
  Biliary leakage (present:absent)12:1323:737:512:80.093
  Surgical site infection (present:absent)11:1334:724:543:70.021

a median (25–75 percentile). GPS, Glasgow prognostic score; HBV, hepatitis B virus; HCV, hepatitis C virus; ICGR15, retention rate of indocyanine green at 15 min; RC, red cell concentrate; FFP, fresh frozen plasma.

Univariate analysis of clinicopathologic variables in relation to disease-free as well as overall survival after hepatic resection for hepatocellular carcinoma

Table II lists univariate analysis of the relationship between the clinicopathologic variables and disease-free as well as overall survival after hepatic resection for HCC. In univariate analysis of disease-free survival, ≥65 years of age (P=0.015), >20 ng/ml of preoperative serum AFP (P=0.015), tumor number of triple or more (P=0.003), positive portal or venous invasion (P=0.048), and GPS 2 (Fig. 1A; P=0.036) demonstrated significant correlating with cancer recurrence. In overall survival, >5 cm of maximal tumor diameter (P=0.011), tumor number of triple or more (P=0.017), positive portal or venous invasion (P<0.001), and GPS 1 (Fig. 1B; P=0.022) and GPS 2 (P<0.001) were significantly associated with poor outcome. More than 200 ng/ml of preoperative serum AFP tended to be associated with poor overall survival, which however was not significant (P=0.070).

Table II.

Univariate analysis of clinicopathologic variables in relation to disease-free and overall survival after elective hepatic resection for hepatocellular carcinoma.

Table II.

Univariate analysis of clinicopathologic variables in relation to disease-free and overall survival after elective hepatic resection for hepatocellular carcinoma.

Disease-free survivalOverall survival


FactorNHazard ratio (95% CI)P-valueHazard ratio (95% CI)P-value
Age (years)
  ≥65  661.660 (1.123–2.660)0.0151.590 (0.7966–3.249)0.186
  <65  78Ref Ref
Sex
  Female  191.159 (0.5641–2.438)0.6721.610 (0.5709–5.571)0.322
  Male125Ref Ref
Body mass index
  ≥25  430.836 (0.5344–1.319)0.4510.6755 (0.3258–1.493)0.355
  <25101Ref Ref
Hepatitis virus
  HBV  380.732 (0.413–1.297)0.2850.838 (0.318–2.203)0.719
  HCV  551.170 (0.725–1.888)0.5211.294 (0.579–2.893)0.530
  None  51Ref Ref
Child's classification
  B  101.350 (0.5885–3.412)0.4412.367 (0.8056–16.04)0.095
  A134Ref Ref
ICGR15
  >10  861.217 (0.8024–1.860)0.3581.402 (0.6954–2.795)0.351
  ≤1058Ref Ref
Serum α-fetoprotein (ng/ml)
  >20  601.407 (0.9260–2.210)0.0151.878 (0.9483–3.964)0.070
  ≤20  84Ref Ref
Type of resection
  Anatomical  780.9672 (0.6364–1.468)0.8741.755 (0.8796–3.519)0.114
  Partial  66Ref Ref
Duration of operation (min)
  ≥360  771.198 (0.7917–1.826)0.3930.8851 (0.4420–1.768)0.729
  <360  67Ref Ref
Intraoperative blood loss (g)
  ≥1,000  541.400 (0.9207–2.223)0.1141.712 (0.8590–3.612)0.123
  <1,000  90Ref Ref
RC transfusion
  Present  331.443 (0.8914–2.549)0.1271.657 (0.7659–4.135)0.181
  Absent111Ref Ref
FFP transfusion
  Present  261.357 (0.7836–2.526)0.2551.794 (0.8126–4.952)0.131
  Absent118Ref Ref
Tumor diameter (cm)
  >5  381.156 (0.831–1.607)0.3892.061 (1.179–3.601)0.011
  >2, ≤5  750.963 (0.727–1.275)0.7911.129 (0.666–1.914)0.653
  ≤2  31Ref Ref
Tumor number
  Triple or more  172.472 (1.352–4.522)0.0032.853 (1.207–6.744)0.017
  Double  131.180 (0.563–2.473)0.6600.791 (0.186–3.367)0.751
  Single114Ref Ref
Portal or venous invasion
  Positive  331.591 (1.010.2.925)0.0484.483 (3.279.18.43)<0.001
  Negative111Ref Ref
Glasgow prognostic score
  2  102.258 (1.054.4.836)0.0367.446 (2.656.20.879)<0.001
  1  581.503 (0.963.2.346)0.0732.530 (1.146.5.585)0.022
  0  76Ref Ref

[i] HBV, Hepatitis B virus; HCV, hepatitis C virus; ICGR15, retention rate of indocyanine green at 15 min; RC, red cell concentrate; FFP, fresh frozen plasma; GPS, Glasgow prognostic score; CI, confidence interval.

Multivariate analysis of clinicopathologic variables in relation to disease-free as well as overall survival after hepatic resection for hepatocellular carcinoma

Table III lists multivariate analysis of the relationship between the clinicopathologic variables and disease-free as well as overall survival after hepatic resection for HCC. In multivariate analysis of disease-free survival, tumor number of triple or more (P=0.004), positive portal or venous invasion (P=0.034), and GPS 2 (P=0.019) were independent risk factors of cancer recurrence. In overall survival, positive portal or venous invasion (P=0.034), and GPS 1 (P=0.042) or GPS 2 (P<0.001) were independent risk factors of poor outcome.

Table III.

Multivariate analysis of clinicopathologic variables in relation to disease-free and overall survival after elective hepatic resection for hepatocellular carcinoma.

Table III.

Multivariate analysis of clinicopathologic variables in relation to disease-free and overall survival after elective hepatic resection for hepatocellular carcinoma.

Disease-free survivalOverall survival


FactorNHazard ratio (95% CI)P-valueHazard ratio (95% CI)P-value
Tumor number
  Triple or more  172.468 (1.333–4.571)0.004
  Double  131.383 (0.653–2.933)0.397
  Single114Ref
Portal or venous invasion
  Positive  331.680 (1.041–2.713)0.0344.494 (2.226–9.073)<0.001
  Negative111Ref Ref
Glasgow prognostic score
  2  102.527 (1.163–5.490)0.0198.012 (2.818–22.784)<0.001
  1  581.392 (0.882–2.198)0.1562.277 (1.029–5.039)0.042
  0  76Ref Ref

[i] GPS, Glasgow prognostic score; CI, confidence interval.

Discussion

Recent studies have reported the prognostic significance of the preoperative inflammation-based scores, such as the GPS, the neutrophil to lymphocyte ratio (23), the platelet to lymphocyte ratio (24), the Prognostic index (25), and the Prognostic nutritional index (26). An inflammatory response to the tumor leads to tumor proliferation and metastasis due to inhibition of apoptosis and promotion of angiogenesis (2730). The GPS is a clinically useful inflammation-based prognostic scoring system for predicting the postoperative prognosis of the patients with colorectal cancer (9), esophageal cancer (10), bladder cancer (11), pancreatic head cancer (12), renal clear cell cancer (13), non-small cell lung cancer (14), and HCC (18,19). The GPS is evaluated using only serum CRP and serum albumin, which are common laboratory parameters for assessment of pre- and postoperative patients status. Therefore the GPS could stratify the patients with malignant tumors on prognosis after surgical resection easily, less-expensive, and less-invasive. Most HCC patients suffered from chronic hepatitis or cirrhosis, and synthesis of protein such as CRP and albumin are impaired.

Disease-free survival is probably affected by remnant liver volume and remnant liver functional reserve. We hope to show the relationship between remnant liver volume and therapeutic outcome after hepatic resection for HCC in future study.

In this study, tumor number of 3 or more, positive portal or venous invasion, and GPS 2 were independent risk factors of cancer recurrence in multivariate analysis. Positive portal or venous invasion, and GPS 1 and 2 were also independent risk factors of poor overall survival in multivariate analysis. To the best of our knowledge, this is the first study that patients were clearly stratified on risk of poor overall survival after hepatic resection for HCC with respect to grade of the GPS. Moreover, on postoperative infectious complications, the incidence of surgical site infection was greater, and that of biliary leakage tended to correlate with the GPS grade in univariate analysis. Therefore, the GPS may be able to stratify the patients with HCC on risks of postoperative complications as well as cancer recurrence and prognosis after hepatic resection.

The GPS upon diagnosis in patients with HCC was an independent predictor in disease-free and overall survival after hepatic resection. Measurement of GPS may help decision making in the post-operative management of patients with HCC.

References

1 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM and Wong J: Improving survival results after resection of hepatocellular carcinoma: A prospective study of 377 patients over 10 years. Ann Surg. 234:63–70. 2001. View Article : Google Scholar : PubMed/NCBI

3 

Poon RT, Ng IO, Fan ST, Lai EC, Lo CM, Liu CL and Wong J: Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: A study of a prospective cohort. J Clin Oncol. 19:3037–3044. 2001. View Article : Google Scholar : PubMed/NCBI

4 

Katz SC, Shia J, Liau KH, Gonen M, Ruo L, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH and Dematteo RP: Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg. 249:617–623. 2009. View Article : Google Scholar : PubMed/NCBI

5 

Arii S, Tanaka J, Yamazoe Y, Minematsu S, Morino T, Fujita K, Maetani S and Tobe T: Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. Cancer. 69:913–919. 1992. View Article : Google Scholar : PubMed/NCBI

6 

Yanaga K: Current status of hepatic resection for hepatocellular carcinoma. J Gastroenterol. 39:919–926. 2004. View Article : Google Scholar : PubMed/NCBI

7 

Shiba H, Ishida Y, Wakiyama S, Iida T, Matsumoto M, Sakamoto T, Ito R, Gocho T, Furukawa K, Fujiwara Y, Hirohara S, et al: Negative impact of blood transfusion on recurrence and prognosis of hepatocellular carcinoma after hepatic resection. J Gastrointest Surg. 13:1636–1642. 2009. View Article : Google Scholar : PubMed/NCBI

8 

Tandon P and Garcia-Tsao G: Prognostic indicators in hepatocellular carcinoma: A systematic review of 72 studies. Liver Int. 29:502–510. 2009. View Article : Google Scholar : PubMed/NCBI

9 

McMillian DC, Crozier JE, Canna K, Angerson WJ and McArdle CS: Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 22:881–886. 2007. View Article : Google Scholar : PubMed/NCBI

10 

Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ and Stuart RC: An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 94:1568–1571. 2006.PubMed/NCBI

11 

Hilmy M, Bartlett JM, Underwood MA and McMillan DC: The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer. 92:625–627. 2005. View Article : Google Scholar : PubMed/NCBI

12 

Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R and Imrie CW: Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer. 92:21–23. 2005. View Article : Google Scholar : PubMed/NCBI

13 

Lamb GW, Aitchison M, Ramsey S, Housley SL and McMillan DC: Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: Basis of new prognostic scoring systems. Br J Cancer. 106:279–283. 2012. View Article : Google Scholar : PubMed/NCBI

14 

Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T, Enomoto Y and Onitsuka T: Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res. 27:3001–3004. 2007.PubMed/NCBI

15 

Shiba H, Misawa T, Fujiwara Y, Futagawa Y, Furukawa K, Haruki K, Iwase R, Wakiyama S, Ishida Y and Yanaga K: Glasgow prognostic score predicts therapeutic outcome after pancreaticoduodenectomy for carcinoma of the ampulla of vater. Anticancer Res. 33:2715–2721. 2013.PubMed/NCBI

16 

Shiba H, Iwase R, Futagawa Y, Futagawa Y, Furukawa K, Haruki K, Iwase R, Iida T and Yanaga K: Glasgow prognostic score predicts therapeutic outcome after surgical resection for gallbladder cancer. World J Surg. 39:753–758. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Furukawa K, Shiba H, Haruki K, Fujiwara Y, Iida T, Mitsuyama Y, Ogawa M, Ishida Y, Misawa T and Yanaga K: The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases. Oncol Lett. 4:324–328. 2012.PubMed/NCBI

18 

Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M and Sawada T: Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: A retrospective study of 398 Japanese patients. Am J Surg. 203:101–106. 2012. View Article : Google Scholar : PubMed/NCBI

19 

Horino K, Beppu T, Kuroki H, Mima K, Okabe H, Nakahara O, Ikuta Y, Chikamoto A, Ishiko T, Takamori H and Baba H: Glasgow prognostic score as a useful prognostic factor after hepatectomy for hepatocellular carcinoma. Int J Clin Oncol. 18:829–838. 2013. View Article : Google Scholar : PubMed/NCBI

20 

Miyagawa S, Makuuchi M, Kawasaki S and Kakazu T: Criteria for safe hepatic resection. Am J Surg. 169:589–594. 1995. View Article : Google Scholar : PubMed/NCBI

21 

Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L, Fan ST, Yokoyama Y, Crawford M, Makuuchi M, et al: Bile leakage after hepatobiliary and pancreatic surgery: A definition and grading of severity by the International Study Group of Liver Surgery. Surgery. 149:680–688. 2011. View Article : Google Scholar : PubMed/NCBI

22 

Mangram AJ, Horan TC, Pearson ML, Silver LC and Jarvis WR: Guideline for prevention of surgical site infection, 1999. Centers for disease control and prevention (CDC) hospital infection control practices advisory committee. Am J Infect Control. 27:97–134; 96. 1999. View Article : Google Scholar : PubMed/NCBI

23 

Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, et al: Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis. 25:1427–1433. 2010. View Article : Google Scholar : PubMed/NCBI

24 

Shirai Y, Shiba H, Sakamoto T, Horiuchi T, Haruki K, Fujiwara Y, Futagawa Y, Ohashi T and Yanaga K: Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Surgery. 158:360–365. 2015. View Article : Google Scholar : PubMed/NCBI

25 

Kasymjanova G, MacDonald N, Agulnik JS, Cohen V, Pepe C, Kreisman H, Sharma R and Small D: The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol. 17:52–58. 2010. View Article : Google Scholar : PubMed/NCBI

26 

Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S and Nakao A: Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 98:268–274. 2011. View Article : Google Scholar : PubMed/NCBI

27 

Balkwill F and Mantovani A: Inflammation and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI

28 

Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI

29 

Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI

30 

Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

July-2017
Volume 14 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shiba H, Horiuchi T, Sakamoto T, Furukawa K, Shirai Y, Iida T, Fujiwara Y, Haruki K and Yanaga K: Glasgow prognostic score predicts therapeutic outcome after hepatic resection for hepatocellular carcinoma. Oncol Lett 14: 293-298, 2017
APA
Shiba, H., Horiuchi, T., Sakamoto, T., Furukawa, K., Shirai, Y., Iida, T. ... Yanaga, K. (2017). Glasgow prognostic score predicts therapeutic outcome after hepatic resection for hepatocellular carcinoma. Oncology Letters, 14, 293-298. https://doi.org/10.3892/ol.2017.6104
MLA
Shiba, H., Horiuchi, T., Sakamoto, T., Furukawa, K., Shirai, Y., Iida, T., Fujiwara, Y., Haruki, K., Yanaga, K."Glasgow prognostic score predicts therapeutic outcome after hepatic resection for hepatocellular carcinoma". Oncology Letters 14.1 (2017): 293-298.
Chicago
Shiba, H., Horiuchi, T., Sakamoto, T., Furukawa, K., Shirai, Y., Iida, T., Fujiwara, Y., Haruki, K., Yanaga, K."Glasgow prognostic score predicts therapeutic outcome after hepatic resection for hepatocellular carcinoma". Oncology Letters 14, no. 1 (2017): 293-298. https://doi.org/10.3892/ol.2017.6104